Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3121 - 3128 of 12089 results
Webinar Recording: Vaccination and the Workplace – Solving for the Latest Challenges Facing Employers
June 17, 2021| Webinar| Viewpoint
EXCLUSIVE RIGHTS: Intellectual Property — Descriptive v. Distinctive: How to Brand Your Business and Products
June 17, 2021| Podcast| Viewpoint
Health Law Diagnosed — Women in Health Law: Leadership, Mentorship, and Beyond
June 17, 2021| Podcast| Viewpoint
Reduced Scope of March-in Rights Under Bayh Dole Rules Revisions
June 16, 2021| Blog| Viewpoint
Roundtable: Shareholder Disputes
June 16, 2021| News
U.S. Citizenship and Immigration Services Issues Policy Updates to Improve Legal Immigration Processes
June 16, 2021| Alert| Viewpoint
Monthly TCPA Digest — June 2021
June 15, 2021| Article| Viewpoint
TCPA Litigation Update — District Courts Continue to Clarify the Impact of Facebook
June 15, 2021| Article| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|